作者
Philipp B Staber, Marco Herling, Mar Bellido, Eric D Jacobsen, Matthew S Davids, Tapan Mahendra Kadia, Andrei Shustov, Olivier Tournilhac, Emmanuel Bachy, Francesco Zaja, Kimmo Porkka, Gregor Hoermann, Ingrid Simonitsch-Klupp, Claudia Haferlach, Stefan Kubicek, Marius E Mayerhoefer, Georg Hopfinger, Ulrich Jaeger, Claire Dearden
发表日期
2019/10/3
来源
Blood, The Journal of the American Society of Hematology
卷号
134
期号
14
页码范围
1132-1143
出版商
American Society of Hematology
简介
T-cell prolymphocytic leukemia (T-PLL) is a rare, mature T-cell neoplasm with a heterogeneous clinical course. With the advent of novel treatment options that will potentially change the management of patients with T-PLL, it has become necessary to produce consensus guidelines for the design and conduct of clinical trials. The T-PLL International Study group (TPLL-ISG) set out to define standardized criteria for diagnosis, treatment indication, and evaluation of response. These criteria will facilitate comparison of results from clinical trials in T-PLL, and will thus support clinical decision making, as well as the approval of new therapeutics by healthcare authorities.
学术搜索中的文章
PB Staber, M Herling, M Bellido, ED Jacobsen… - Blood, The Journal of the American Society of …, 2019